{
    "clinical_study": {
        "@rank": "84192", 
        "brief_summary": {
            "textblock": "To test the effectiveness of recombinant human CD4 Immunoglobulin G (CD4-IgG) in the\n      treatment of HIV-associated immune thrombocytopenic purpura in patients with all levels of\n      HIV infection."
        }, 
        "brief_title": "A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura", 
        "condition": [
            "Immune Thrombocytopenic Purpura ( ITP )", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Purpura", 
                "Purpura, Thrombocytopenic", 
                "Purpura, Thrombocytopenic, Idiopathic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Dapsone at a constant dose level and only as a prophylaxis for Pneumocystis carinii\n             pneumonia (PCP).\n\n          -  Zidovudine (AZT) at a constant dose for the 12 weeks of treatment, except if\n             AZT-related toxicity is observed.\n\n        Patients must have the following:\n\n          -  HIV seropositive (asymptomatic, AIDS-related complex, or AIDS).\n\n          -  HIV-associated immune thrombocytopenic purpura.\n\n          -  The ability to sign a written informed consent form, which must be obtained prior to\n             treatment.\n\n          -  A willingness to abstain from all other experimental therapy for HIV infection during\n             the entire study period.\n\n          -  Patients currently on zidovudine are not excluded.  However, the zidovudine dose\n             level must remain constant for 4 weeks prior to entry and for the 12 weeks of\n             treatment, except if zidovudine related toxicity is observed.\n\n          -  A life expectancy of at least 3 months.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Dapsone at a constant dose for more than 2 weeks prior to study entry.\n\n          -  Zidovudine at a constant dose for 4 weeks prior to study entry.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions and symptoms are excluded:\n\n          -  Active serious opportunistic infection (excluding positive block cultures of\n             Mycobacterium avium complex or Cytomegalovirus).\n\n          -  Malignancies other than Kaposi's sarcoma.\n\n          -  Tumor-associated edema.\n\n          -  Visceral Kaposi's sarcoma.\n\n          -  Significant neurologic, cardiac, or liver disease.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Ganciclovir (DHPG). Pyrimethamine. Clindamycin. Sulfadiazine. Folinic acid.\n             Prednisone. Intravenous gamma globulin. Intravenous acyclovir. Interferon. Systemic\n             corticosteroids. Non-steroidal anti-inflammatory drugs (NSAIDs). Known\n             immunomodulatory agents. Dideoxycytosine. Dideoxyinosine. Nucleoside analogs (with\n             the exception of zidovudine or topical acyclovir). Any experimental therapy.\n\n        Patients with the following are excluded:\n\n          -  Active serious opportunistic infection (excluding positive block cultures of\n             Mycobacterium avium complex or Cytomegalovirus).\n\n          -  Malignancies other than Kaposi's sarcoma.\n\n          -  Kaposi's sarcoma requiring therapy.\n\n          -  Tumor-associated edema.\n\n          -  Visceral Kaposi's sarcoma.\n\n          -  Significant neurologic, cardiac, or liver disease.\n\n          -  Conditions requiring excluded concomitant medications.\n\n          -  Herpes virus infection requiring intravenous acyclovir.\n\n        Prior Medication:\n\n        Excluded for a minimum of 4 weeks prior to study entry:\n\n          -  Chemotherapy.\n\n          -  Immunomodulatory agents.\n\n          -  Any experimental therapy.\n\n        Prior Treatment:\n\n        Excluded for a minimum of 4 weeks prior to study entry:\n\n          -  Radiation therapy.\n\n          -  Any experimental therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002250", 
            "org_study_id": "076A", 
            "secondary_id": "D0177g"
        }, 
        "intervention": {
            "intervention_name": "CD4-IgG", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Immunoglobulin G", 
                "Immunoglobulins", 
                "Antibodies", 
                "CD4 Immunoadhesins"
            ]
        }, 
        "keyword": [
            "Recombinant Proteins", 
            "IgG", 
            "Drug Evaluation", 
            "Antigens, CD4"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "941102859"
                }, 
                "name": "San Francisco Gen Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Kahn J, Hassner A, Arri C, Coleman R, Kaplan L, Volberding P, Ammann A, Abrams D. A phase 1 study of recombinant human CD4 immunoglobulin g (rCD4-IgG) in patients with HIV-associated immune thrombocytopenic purpura. Int Conf AIDS. 1991 Jun 16-21;7(2):221 (abstract no WB2156)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002250"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1991"
    }, 
    "geocoordinates": {
        "San Francisco Gen Hosp": "37.775 -122.419"
    }
}